Morphogenesis, Inc.
Morphogenesis, Inc.
  • Home
    • Scientific Overview
    • Publications
    • Pipeline
    • Clinical Trials
    • Our Philosophy
    • Our Team
    • Our Executive Board
    • Our Intellectual Property
    • Our Bio Facility
    • Newsroom
    • Home
    • Our Science
      • Scientific Overview
      • Publications
    • Clinical Trials
      • Pipeline
      • Clinical Trials
    • About Us
      • Our Philosophy
      • Our Team
      • Our Executive Board
      • Our Intellectual Property
      • Our Bio Facility
      • Newsroom
  • Home

Scientific Overview

ImmuneFx Personalized Immunotherapy Platform

 While most immunotherapies focus on a single aspect of cancer immunity, ImmuneFx modulates the tumor microenvironment in multiple ways by priming, generating, guiding and augmenting both innate and adaptive immune pathways.

________________________________________________________________________

  • Off-the-shelf products induce personalized anti-tumor effect in situ
  • Requires no patient information for manufacturing
  • Requires no patient information for effectiveness
  • Robust, comprehensive polyvalent immune response
  • Multiple types of immune cells (innate and adaptive) in inflamed tumor microenvironment
  • Systemic response to multiple tumor antigens through optimal antigen presentation/T cell priming and epitope spreading
  • Automatically educates naïve T cells to their cognate neoantigens
  • Leverages mutational load to take advantage of maximum number of tumor antigen targets
  • Broadly applicable to all solid tumors/lymphomas
  • No possibility of viral recombination or systemic infection by live viruses or bacteria
  • Multiple delivery options
  • Tested in multiple naturally occurring cancers in multiple large animal species
  • No product-related serious adverse events in preclinical studies and clinical trials demonstrated
  • Products can be produced quickly and at very low cost compared to other therapies

image403

Mechanism of Action

image404

TME=tumor microenvironment; APCs=antigen presenting cells

Cancer Immunity: A Clear Difference Between Approaches

image405

Safety and Disease Control Effects

Murine Neuroblastoma Pre-clinical Study

Canine B Cell Lymphoma Nonclinical Study

Canine B Cell Lymphoma Nonclinical Study

image406

  • Strong humoral & cell-mediated responses
  • Prevented tumor formation in 100% of mice and increased survival in challenged mice by 81% (N=259)
  • Increased long-term survival by 88%
  • Promoted massive infiltration of lymphocytes
  • Dose-dependent therapeutic effect
  • No Adverse Events or Serious Adverse Events


 __________________________________________________ 

Canine B Cell Lymphoma Nonclinical Study

Canine B Cell Lymphoma Nonclinical Study

Canine B Cell Lymphoma Nonclinical Study

image407

  • Enhanced survival:
    • Untreated (historical) 7-59 days
    • Standard-of-care (historical) = 183-365 days
  • IFx-CL alone (N=17)
    • Median survival time: 123 days
  • IFx-CL + Standard-of-care (N = 10)
    • Median ongoing survival: 389 days
  • Strong humoral & cell-mediated responses
  •  No Adverse Events or Serious Adverse Events

 __________________________________________________ 

Equine Melanoma USDA Field Study

Murine Melanoma Pre-clinical Study

Murine Melanoma Pre-clinical Study

image408

  • Response: % change in total (injected/noninjected) tumor burden (RECIST v1.1/VCOG) between weeks 1-35 (N=22)
    • PD = 0/22 = 0%
    • PR = 6/22 = 27%
    • SD = 16/22= 73%
    • Tumor regression = 17/22 = 77%
  • Humoral & CD4+ & CD8+ cellular responses
  •  No Adverse Events or Serious Adverse Events

___________________________________________________ 

Murine Melanoma Pre-clinical Study

Murine Melanoma Pre-clinical Study

Murine Melanoma Pre-clinical Study

image409

  • Strong humoral & cell-mediated responses
  • pAc/emm55 plus anti-PD-1 Antibody delayed tumor growth & increased survival (N=257)
  • INF-ϒ production by dendritic cells
  • Enhanced CD4+/CD8+ T cell tumor infiltration
  • Systemic immune response dependent on both CD4+/CD8+ 
  •  No Adverse Events or Serious Adverse Events


___________________________________________________

Filling the Void

image410

 ImmuneFx  has the potential to  broaden the applicability of checkpoint blockades by priming robust, patient-specific, multivalent responses in naïve, unresponsive, or refractory patients 

Copyright © 2021 Morphogenesis, Inc. - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept